ES8601233A1 - Procedimiento para la preparacion de tigogenin-celebiosido - Google Patents

Procedimiento para la preparacion de tigogenin-celebiosido

Info

Publication number
ES8601233A1
ES8601233A1 ES534553A ES534553A ES8601233A1 ES 8601233 A1 ES8601233 A1 ES 8601233A1 ES 534553 A ES534553 A ES 534553A ES 534553 A ES534553 A ES 534553A ES 8601233 A1 ES8601233 A1 ES 8601233A1
Authority
ES
Spain
Prior art keywords
tigogenin
procedure
preparation
celebioside
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES534553A
Other languages
English (en)
Spanish (es)
Other versions
ES534553A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Research Foundation of Oregon
Original Assignee
Medical Research Foundation of Oregon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Research Foundation of Oregon filed Critical Medical Research Foundation of Oregon
Publication of ES534553A0 publication Critical patent/ES534553A0/es
Publication of ES8601233A1 publication Critical patent/ES8601233A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0015—Details of inhalators; Constructional features thereof with inhalation check valves located upstream of the dispenser, i.e. not traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0013—Details of inhalators; Constructional features thereof with inhalation check valves
    • A61M15/0016—Details of inhalators; Constructional features thereof with inhalation check valves located downstream of the dispenser, i.e. traversed by the product
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0086—Inhalation chambers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Cephalosporin Compounds (AREA)
ES534553A 1984-04-20 1984-07-23 Procedimiento para la preparacion de tigogenin-celebiosido Expired ES8601233A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/602,298 US4602005A (en) 1982-05-17 1984-04-20 Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Publications (2)

Publication Number Publication Date
ES534553A0 ES534553A0 (es) 1985-11-16
ES8601233A1 true ES8601233A1 (es) 1985-11-16

Family

ID=24410793

Family Applications (1)

Application Number Title Priority Date Filing Date
ES534553A Expired ES8601233A1 (es) 1984-04-20 1984-07-23 Procedimiento para la preparacion de tigogenin-celebiosido

Country Status (16)

Country Link
US (1) US4602005A (enExample)
EP (1) EP0159431B1 (enExample)
JP (1) JPS60224697A (enExample)
KR (1) KR940002114B1 (enExample)
AT (1) ATE42959T1 (enExample)
AU (1) AU580005B2 (enExample)
CA (1) CA1246544A (enExample)
DE (1) DE3478114D1 (enExample)
DK (2) DK165839C (enExample)
ES (1) ES8601233A1 (enExample)
FI (2) FI82253C (enExample)
HU (1) HUT37802A (enExample)
IE (1) IE58015B1 (enExample)
NO (1) NO842990L (enExample)
NZ (1) NZ208961A (enExample)
ZA (1) ZA845690B (enExample)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis
US4865850A (en) * 1986-09-08 1989-09-12 See/Shell Biotechnology, Inc. Dietary fat reduction
US5010185A (en) * 1989-06-13 1991-04-23 Pfizer Inc. Processes for tigogenin beta-cellobioside
US5091192A (en) * 1990-01-16 1992-02-25 Natur-All Systems, Inc. Bile salts permanently bound to insoluble cellulose as a dietary supplement
CA2079544A1 (en) * 1991-10-04 1993-04-05 Adam Weislaw Mazur Cholesterol lowering compounds
AU2753292A (en) * 1991-10-04 1993-05-03 Procter & Gamble Company, The Cholesterol lowering compounds and process for making them
WO1993011150A1 (en) * 1991-11-25 1993-06-10 Pfizer Inc. Method for making steroidal peracyl glycosides
US5294703A (en) * 1992-05-01 1994-03-15 Eastman Kodak Company Process for preparing α-D-cellobiose octaacetate
EP0647233A1 (en) * 1992-06-26 1995-04-12 Pfizer Inc. Steroidal beta-o-cellobioside heptaalkanoate process
US5629295A (en) * 1992-06-26 1997-05-13 Pfizer Inc. Steroidal glycosides for treating hypercholesterolemia
CA2138042A1 (en) * 1992-06-26 1994-06-01 Frank R. Busch Process for steroidal peracyl glycosides
US5530107A (en) * 1992-10-15 1996-06-25 Pfizer Inc. Method for making steroidal peracyl glycosides
CA2161239A1 (en) * 1993-04-28 1994-11-10 Douglas J.M. Allen Spirostanyl glycosidal crystalline monohydrate
US5502038A (en) * 1993-06-21 1996-03-26 Medical Research Foundation Of Oregon Cholesterol sequestrant glycosides that inhibit intestinal cholesterol absorption
WO1995000158A1 (en) * 1993-06-25 1995-01-05 Bio-Sphere Technology Dietary supplement incorporating beta-sitosterol and pectin
ES2074006B1 (es) * 1993-07-05 1996-03-16 Pfizer Glicosidos esteroidales para tratar hipercolesterolemia.
US5698526A (en) * 1993-12-28 1997-12-16 Pfizer Inc. Steroidal glycosides
US5607841A (en) * 1994-06-20 1997-03-04 Lipinski; Boguslaw Preparation and proteolytic degradation of a macromolecular protein complex from fibrinogen
AU2453295A (en) * 1994-09-20 1996-04-19 Pfizer Inc. Combination of a cholesterol absorption inhibitor and a cholesterol synthesis inhibitor
WO1996038466A1 (en) * 1995-05-29 1996-12-05 Pfizer Inc. Steroidal glycosides
US5698527A (en) * 1995-08-08 1997-12-16 Merck & Co., Inc. Steroidal glycosides as antihyperlipidemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
PL195897B1 (pl) * 1998-03-26 2007-11-30 Phytopharm Plc Zastosowanie smilageniny
GB9923076D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923078D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB9923077D0 (en) * 1999-09-29 1999-12-01 Phytopharm Plc Sapogenin derivatives and their use
GB0000228D0 (en) * 2000-01-06 2000-03-01 Phytopharm Plc Fluoro substituted sapogenins and their use
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) * 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
US20020183305A1 (en) * 2001-01-26 2002-12-05 Schering Corporation Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
PL364178A1 (en) * 2001-01-26 2004-12-13 Schering Corporation Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
DK1355644T3 (da) * 2001-01-26 2006-10-23 Schering Corp Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
HU230253B1 (hu) * 2001-01-26 2015-11-30 Merck Sharp & Dohme Corp Peroxiszóma proliferátor-aktivált receptor (PPAR) aktivátor(ok) és szterin-abszorpció inhibitor(ok) kombinációi és alkalmazásuk vaszkuláris indikációk kezelésére
IL156585A0 (en) * 2001-01-26 2004-01-04 Schering Corp Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
AU2002241956A1 (en) * 2001-01-26 2002-08-06 Schering Corporation Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
GB0107822D0 (en) * 2001-03-28 2001-05-23 Phytopharm Plc Sapogenin derivatives their synthesis and use methods based upon their use
JP2004532868A (ja) * 2001-05-25 2004-10-28 シェーリング　コーポレイション アルツハイマー病の処置におけるアゼチジノン置換誘導体の使用
US7053080B2 (en) * 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030119808A1 (en) * 2001-09-21 2003-06-26 Schering Corporation Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
AU2002335770B2 (en) * 2001-09-21 2005-08-18 Merck Sharp & Dohme Corp. Methods for treating or preventing vascular inflammation using sterol absorption inhibitor(s)
JP2005504091A (ja) * 2001-09-21 2005-02-10 シェーリング　コーポレイション ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
CN102727501A (zh) * 2002-03-27 2012-10-17 菲特法姆股份有限公司 皂角苷配基及其衍生物的用途
US20050130948A1 (en) * 2002-03-27 2005-06-16 Daryl Rees Therapeutic methods and uses of sapogenins and their derivatives
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
CA2517571C (en) * 2003-03-07 2011-07-05 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (ja) * 2003-03-07 2006-08-31 シェーリング　コーポレイション 置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
EP1680189A2 (en) * 2003-11-05 2006-07-19 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
GB0329667D0 (en) * 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
AU2003300732A1 (en) * 2003-12-31 2005-07-21 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from chlorophytum nimonii
US7160866B2 (en) 2004-03-22 2007-01-09 Council Of Scientific And Industrial Research Isolation of tigogenin pentaglycoside from Chlorophytum nimonii

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2759171A1 (de) * 1977-12-31 1979-07-12 Roecar Holdings Nv Arzneimittel mit wirkung als prostaglandinsynthetaseninhibitor
DE2926463A1 (de) * 1978-07-05 1980-01-24 Roecar Holdings Nv Spiroketaline und ihre verwendung
US4260603A (en) * 1979-01-02 1981-04-07 Pegel Karl H Sterol glycoside with activity as prostaglandin synthetase inhibitor
US4242502A (en) * 1979-04-20 1980-12-30 United States Of America Enhancement of cholesterol combining properties of saponins
US4602003A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Synthetic compounds to inhibit intestinal absorption of cholesterol in the treatment of hypercholesterolemia
US4602005A (en) * 1982-05-17 1986-07-22 Medical Research Foundation Of Oregon Tigogenin cellobioside for treating hypercholesterolemia and atherosclerosis

Also Published As

Publication number Publication date
CA1246544A (en) 1988-12-13
DK14892A (da) 1992-02-06
ATE42959T1 (de) 1989-05-15
JPH0456840B2 (enExample) 1992-09-09
DK165839C (da) 1993-06-21
ES534553A0 (es) 1985-11-16
KR850007432A (ko) 1985-12-04
EP0159431B1 (en) 1989-05-10
FI900531A0 (fi) 1990-02-02
DK361084D0 (da) 1984-07-23
FI82253C (fi) 1991-02-11
FI82253B (fi) 1990-10-31
NZ208961A (en) 1988-01-08
EP0159431A2 (en) 1985-10-30
FI87792B (fi) 1992-11-13
AU580005B2 (en) 1988-12-22
DK165839B (da) 1993-01-25
HUT37802A (en) 1986-02-28
DK14892D0 (da) 1992-02-06
JPS60224697A (ja) 1985-11-09
ZA845690B (en) 1986-03-26
AU3097784A (en) 1985-10-24
NO842990L (no) 1985-10-21
KR940002114B1 (ko) 1994-03-17
IE841904L (en) 1985-10-20
DK166213C (da) 1993-08-16
DE3478114D1 (en) 1989-06-15
US4602005A (en) 1986-07-22
EP0159431A3 (en) 1986-01-08
FI842935A0 (fi) 1984-07-23
DK166213B (da) 1993-03-22
FI87792C (fi) 1993-02-25
IE58015B1 (en) 1993-06-16
DK361084A (da) 1985-10-21
FI842935L (fi) 1985-10-21

Similar Documents

Publication Publication Date Title
ES8601233A1 (es) Procedimiento para la preparacion de tigogenin-celebiosido
FI852974L (fi) Nya n-hydroxylgruppen skyddande grupper och framstaellningsfoerfarande foer 3-acylamino-1-hydroxi-2-azetidinoner.
ES8608472A2 (es) Procedimiento para preparar 2-(bezoil-2-sustituido)-ciclohexano-1, 3-dionas herbicidas
ES8305681A1 (es) Procedimiento para la obtencion de fenileteres sustituidos.
SE8106125L (sv) 4,5-polymetylen-4-isotiazolin-3-oner, sett for framstellning derav och anvendning derav som baktericida och fungicida medel
ES8707731A1 (es) Un procedimiento para la preparacion de derivados de oxindol
ES8306749A1 (es) Un procedimiento para la preparacion de 2-guanidino-4-heteroariltiazoles.
ATE35417T1 (de) Verfahren zur herstellung von phosphorhaltigen cyanhydrinderivaten.
ES8607243A1 (es) Esteres de aminoacidos y de peptidos cromogenos
ES8707942A1 (es) Un procedimiento para preparar eteres fenolicos de oxazolidina
DK518487D0 (da) 7-(meta-substitueret phenylglycin)-1-carba-1-dethiacephalosporiner og fremgangsmaade til fremstilling heraf
ES8200122A1 (es) Un metodo para la preparacion de 17,21-diesteres de 6alfa- 9alfa-didluoro-16-metil-prednisolona
ES8104323A1 (es) Un procedimiento para obtener 2,6-diaminonebularinas
DE3263928D1 (en) Poly(piperidylamine) alkanes and synthetic resin compositions stabilized thereby
NO953347L (no) Triglyserid kontrastmiddel
ES2055708T3 (es) Peptidos.
JPS5758687A (en) Antibiotic
ES8601949A1 (es) Un procedimiento para preparar un derivado de rifanipicina
ES8504197A1 (es) Un procedimiento para la preparacion de un derivado de (1,2,4) triazolo (4,3-a) quinoxalin-4-amina
ES8100282A1 (es) Procedimiento para la obtencion de nuevos derivados de la piperacina metanimina
ES8201171A1 (es) Procedimiento para la obtencion de eteres azolil-silil-gli- colidos de accion fungicida
ES8201532A1 (es) Procedimiento de preparacion de derivados de fenil alcoxi propanolaminas
JPS579754A (en) Preparation of methylene dicarbanilate
JPS56108764A (en) Novel synthesis of beta-blocker
DK452984D0 (da) Fremgangsmaade til fremstilling af quinolin-4-oner

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19971001